Just In
- 50 min ago Backless Dress: 7 Tips For Choosing Perfect Bra For Backless Outfits And Turn Heads Wherever You Go
- 9 hrs ago Summer Style: 6 Must-Try Colors To Stay Fashionably Cool Like B-Town Divas!
- 11 hrs ago Belgian Man Cleared Of Drunk Driving Because His Body Produces Alcohol Due To A Rare Condition
- 12 hrs ago Amitabh Bachchan's Youthful Avatar In Kalki 2898 AD Is Impressive, Check Actors Who Sported Digital De-Aging!
Don't Miss
- Movies After Dalljiet Kaur-Nikhil Patel, Kundali Bhagya Star To DIVORCE Actress-Wife After 2 Yrs Of Marriage? DEETS
- News Delhi Police Joins 'Look Between Your Keyboard' Trend, Gives Witty Driving Warning
- Sports DC vs GT IPL 2024: Why Shubman Gill Held Back Spinner R Sai Kishore Till 19th over?
- Travel Escape to Kalimpong, Gangtok, and Darjeeling with IRCTC's Tour Package; Check Itinerary
- Finance DCB Bank Q4 Results: PAT Grew 9% To Rs 156 Cr, NII Jumps 4.5%; Dividend Declared
- Technology OPPO Find X7 Ultra Camera Deep-Dive: Pushing the Boundaries of Photography on a Smartphone
- Education MP Board Class 10th, 12th Results 2024, Know Alternative Ways to Check Your Result
- Automobiles Aston Martin Vantage Launched In India At Rs 3.99 Crore
Covishield Protection Wanes After Three Months, Lancet Study Finds
The protection offered by the Oxford-Astra Zeneca COVID-19 vaccine declines after three months of receiving two doses of the preventive, according to a study published in The Lancet journal.
The findings drawn from datasets in Brazil and Scotland suggest that booster programmes are needed to help maintain protection from severe disease in those vaccinated with AstraZeneca, known as Covishield in India.
The researchers analysed data for two million people in Scotland and 42 million people in Brazil who had been vaccinated with the AstraZeneca vaccine.
In Scotland, when compared with two weeks after receiving a second dose, there was approximately a fivefold increase in the chance of being hospitalised or dying from COVID-19 nearly five months after being double vaccinated, the researchers said.
The decline in effectiveness begins to first appear at around three months, when the risk of hospitalisation and death is double that of two weeks after the second dose, they said.
The researchers from Scotland and Brazil found that the risk of hospitalisation and death increases threefold just short of four months after the second vaccine dose. Similar numbers were seen for Brazil, they said.
"Vaccines have been a key tool in fighting the pandemic, but waning in their effectiveness has been a concern for a while," said Professor Aziz Sheikh, from the University of Edinburgh, UK.
"By identifying when waning first starts to occur in the Oxford-AstraZeneca vaccine, it should be possible for governments to design booster programmes that can ensure maximum protection is maintained, Sheikh said.
The team was able to compare data between Scotland and Brazil as they had a similar interval between doses - 12 weeks - and initial prioritisation of who was vaccinated - people at highest risk of severe disease and healthcare workers.
The dominant variant was different in each country during the study period - Delta in Scotland and Gamma in Brazil.
This means the decline in effectiveness is likely because of vaccine waning and the impact of variants, according to the researchers.
The study also estimated vaccine effectiveness at similar fortnightly intervals by comparing outcomes of people who have been jabbed with those who are unvaccinated.
However, the experts warned that these figures should be treated with caution because it is becoming harder to compare unvaccinated people to those vaccinated with similar characteristics, particularly among older age groups where so many people are now vaccinated.
"Our analyses of national datasets from both Scotland and Brazil suggest that there is a considerable waning of effectiveness for the Oxford AstraZeneca vaccine, with protection against severe COVID-19 falling over time," said Professor Srinivasa Vittal Katikireddi from the University of Glasgow in the UK.
"Our work highlights the importance of getting boosters, even if you've had two doses of the Oxford AstraZeneca vaccine, as soon as you are able to," Katikiredd added.
- healthCOVID-19 Vaccines and Heart Attacks: New Studies Show Different Results; What Are They?
- wellnessCorbevax Will Be Allowed As A Booster For Those Fully Vaccinated With Covishield Or Covaxin
- wellnessBooster Dose Of COVID Vaccine Needed To Fight Against Omicron: Study
- wellnessCovishield Dose Gap Reduced To 8-16 Weeks From 12-16
- healthEach Dose Of Covishield, Covaxin Likely To Be Capped At Rs 275 After Getting Regular Market Approval
- healthMedia Reports Stating Vaccine Shortage In Maharashtra Are Not Factually Correct: Govt
- healthCovovax Better Booster For Covishield-Vaccinated People: Dr Shahid Jameel, Virologist
- healthCovishield's Effectiveness In Fully Vaccinated Individuals 63% During 2nd Wave, Study
- healthSerum Institute Urges Govt To Fast-Track Movement Of Increasing Covishield Stock
- healthGovernment Allows Serum Institute To Export 50 Lakh Covishield Doses Under Covax To 4 Nations
- healthCovishield May Offer Over 90% Protection Against Death From Delta Variant: Study
- disorders cureMixing And Matching Of COVID-19 Vaccine Doses? Is It Safe?